Hematogones: a new prognostic factor for acute myeloblastic leukemia

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Acute myeloid leukemia (AML) patient outcomes are highly variable.
• Novel prognostic markers are crucial for predicting AML relapse.
• Hematogones (HGs), normal B-lymphocyte precursors, can increase in hematologic malignancies.

Purpose of the Study:

• To investigate the prognostic significance of hematogones in AML patients.
• To assess the impact of HG presence on leukemia-free survival (LFS) and overall survival (OS).
• To determine if HG levels can serve as a predictive tool for AML relapse risk.

Main Methods:

• Flow cytometry was used to analyze HG levels in 120 AML patients in first complete remission.
• Patients were stratified based on HG detection thresholds.
• Cox regression analysis was employed to identify independent predictors of survival.

Main Results:

• Patients with HG levels > 0.01% demonstrated significantly better median LFS (29.2 vs 11.7 months, P = .001).
• Overall survival was also significantly improved in patients with HG levels > 0.01% (not reached vs 23.5 months, P = .011).
• HG level > 0.01% independently predicted better LFS (HR=0.5, P < .03) after adjusting for clinical and molecular factors.

Conclusions:

• Hematogone analysis is a potential prognostic tool for AML.
• Detectable HG levels correlate with improved LFS and OS in AML patients.
• HG assessment may assist in refining risk stratification and predicting relapse in AML.